Mar 7 |
Sight Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Initiates Full Year 2024 Financial Guidance
|
Mar 7 |
Earnings Scheduled For March 7, 2024
|
Feb 22 |
Sight Sciences to Report Fourth Quarter and Full Year 2023 Financial Results on March 7, 2024
|
Feb 21 |
Sight Sciences (SGHT) to Expand in Europe With New Launch
|
Dec 26 |
Sight Sciences climbs after update on Medicare coverage for glaucoma procedure
|
Dec 18 |
Sight Sciences Announces the Publication of Successful Results of the SAHARA Randomized Controlled Clinical Trial Comparing TearCare® to Restasis® for the Treatment of Dry Eye Disease
|
Dec 8 |
Sight Sciences Announces the Acceptance for Publication of GEMINI 2, a Three Year, Prospective, Multicenter Trial Demonstrating Sustained, Significant IOP and Medication Reductions Enabled with the OMNI® Surgical System Technology
|
Nov 24 |
Sight Sciences spikes after insider purchases
|
Nov 24 |
Independent Chairman of Sight Sciences Picks Up 14% More Stock
|
Nov 19 |
The Sight Sciences, Inc. (NASDAQ:SGHT) Analysts Have Been Trimming Their Sales Forecasts
|